top of page
News, Events and Updates
Search
Feb 16, 2011
Anavex Adds Dr. Paul Aisen to Scientific Advisory Board
Jan 18, 2011
Anavex Comments on President Obama’s Signing of National Alzheimer’s Project Act into Law
Jan 6, 2011
Alzheimer’s Weekly Names ANAVEX 2-73 the Number One Most Promising Trial Drug in Alzheimer’s Disease
Dec 21, 2010
Anavex Files Phase I Regulatory Submission for ANAVEX 2-73 in Alzheimer’s Disease
Sep 29, 2010
Anavex Appoints David Tousley as CFO
Sep 12, 2010
ANAVEX 2-73: Journal of Psychopharmacology Publishes Anti-Amnesic and Neuroprotective Data
Sep 10, 2010
Neuroprotective efficacy of ANAVEX 2-73, a novel tetrahydrofuran derivative targeting the sigma-1...
Sep 8, 2010
Anti-amnesic and neuroprotective potentials of the mixed muscarinic receptor/σ1 ligand ANAVEX 2-73
Sep 7, 2010
Anavex to Present at Rodman & Renshaw Healthcare Conference September 13 in New York City
Aug 29, 2010
Dr. Cameron Durrant Named One of PharmaVOICE’s 100 Most Inspiring in the Pharmaceutical Industry
Aug 9, 2010
Anavex Appoints Contract Research Organizations to Initiate Phase I/IIa Clinical Programs
44
45
46
47
48
Stay Connected
Follow us on social media
Newsroom
Webcast Library
Contact Us
Back to Newsroom
bottom of page
